title: Thrombotic Events in Asymptomatic FXII Deficiency versus Symptomatic FXI Deficiency: Surprising Observations.
abstract: To evaluate the impact of an asymptomatic congenital clotting defect (FXII deficiency) versus that of a similar but symptomatic defect (FXI deficiency) on protection from thrombosis.
  
  
  
  All patients with FXII or FXI deficiency and thrombosis were gathered from a time-unlimited PubMed search that was carried out twice and from personal records. Combined defects were excluded. The defect had to be proven by the demonstration of a suited hereditary pattern and by a specific clotting assay. Only patients with a factor activity level of <30% of normal were selected.
  
  
  
  Twenty-eight patients with an FXII deficiency presented with arterial thrombosis, mainly myocardial infarction, and 29 showed venous thrombosis; for FXI deficiency, these figures were 43 and 10, respectively. The ratio of arterial and venous thrombosis was 0.96 and 4.3, respectively, for FXII and FXI deficiency.
  
  
  
  Factor FXII deficiency supplies no protection from arterial or venous thrombosis. FXI deficiency shows no protection from arterial thrombosis but appears to guarantee protection from venous thrombosis. A symptomatic, namely bleeding, condition (FXI deficiency) provides protection from venous thrombosis whereas an asymptomatic one (FXII deficiency) does not.
authors.affiliation: Department of Medicine, University of Padua Medical School, Padua, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Girolami
authors.forename: E
authors.initials: E
authors.lastname: Cosi
authors.forename: C
authors.initials: C
authors.lastname: Santarossa
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
authors.forename: A M
authors.initials: AM
authors.lastname: Lombardi
mesh_terms: D001777:Blood Coagulation; D006801:Humans; D013927:Thrombosis / Q000517:prevention & control*; D013997:Time Factors; D020246:Venous Thrombosis